Predictive Value of XRCC1 and XRCC3 Gene Polymorphisms for Risk of Ovarian Cancer Death After Chemotherapy

Objective: To investigate any association between XRCC1 and XRCC3 polymorphisms and outcome ofplatinum-based chemotherapy in ovarian cancer patients.
Methods: With a prospective study design was caseswere consecutively collected from January 2005 to January 2007. All 310 included patients were followed-upuntil the end of January 2010. Genotyping of XRCC1 and XRCC3 polymorphisms was conducted by TaqManGene Expression assays.
Results: A total of 191 patients died during follow-up. Our study showed a lowersurvival rate in XRCC1 399 Arg/Arg genotype than Gln/ Gln, with a significant increased risk of death (HR=1.69,95%CI=1.07-2.78). Similarly, those carrying XRCC3 Thr/ Thr genotype had a increased risk as compare tothe Met/Met genotype, with a HR (95% CI) of 1.90 (1.12-3.41). There was no significant association betweenXRCC1 Arg194Trp and XRCC1Arg280His gene polymorphisms and ovarian cancer death.
Conclusion: Ourstudy demonstrates that polymorphisms in DNA repair genes have roles in the susceptibility and survival ofovarian cancer patients.